11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies
58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, United States Of America, 3 - 06 December 2016, vol.128, (Summary Text)
- Publication Type: Conference Paper / Summary Text
- Volume: 128
- Doi Number: 10.1182/blood.v128.22.2042.2042
- City: California
- Country: United States Of America
- Dokuz Eylül University Affiliated: Yes